JPMorgan Chase & Co. Grows Stake in Immunome, Inc. (NASDAQ:IMNM)

JPMorgan Chase & Co. grew its holdings in Immunome, Inc. (NASDAQ:IMNM) by 6.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 24,565 shares of the company’s stock after acquiring an additional 1,520 shares during the period. JPMorgan Chase & Co.’s holdings in Immunome were worth $359,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of IMNM. AQR Capital Management LLC lifted its stake in shares of Immunome by 34.6% during the 2nd quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock valued at $194,000 after buying an additional 4,129 shares in the last quarter. Cerity Partners LLC lifted its holdings in shares of Immunome by 10.5% in the 3rd quarter. Cerity Partners LLC now owns 53,103 shares of the company’s stock valued at $776,000 after acquiring an additional 5,043 shares during the last quarter. Primecap Management Co. CA increased its position in shares of Immunome by 4.5% during the 3rd quarter. Primecap Management Co. CA now owns 280,800 shares of the company’s stock valued at $4,105,000 after purchasing an additional 12,000 shares during the last quarter. FMR LLC raised its stake in shares of Immunome by 0.3% in the third quarter. FMR LLC now owns 4,224,700 shares of the company’s stock valued at $61,765,000 after acquiring an additional 13,757 shares during the period. Finally, Intech Investment Management LLC bought a new stake in Immunome in the third quarter worth about $219,000. 44.58% of the stock is owned by institutional investors.

Insider Transactions at Immunome

In other Immunome news, CTO Philip Tsai bought 21,000 shares of the stock in a transaction on Thursday, November 21st. The shares were bought at an average price of $9.43 per share, with a total value of $198,030.00. Following the purchase, the chief technology officer now directly owns 21,000 shares in the company, valued at $198,030. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Robert Lechleider purchased 15,805 shares of the stock in a transaction that occurred on Thursday, November 21st. The shares were acquired at an average price of $9.48 per share, for a total transaction of $149,831.40. Following the completion of the transaction, the insider now directly owns 15,805 shares of the company’s stock, valued at $149,831.40. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders have bought 102,862 shares of company stock valued at $978,045 in the last 90 days. 8.60% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Stephens assumed coverage on shares of Immunome in a research report on Friday, November 8th. They issued an “overweight” rating and a $30.00 price objective for the company. Wedbush restated an “outperform” rating and issued a $33.00 target price on shares of Immunome in a research note on Monday, January 13th. Finally, Piper Sandler lowered their target price on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a research note on Thursday, November 14th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $28.60.

Immunome Stock Up 1.2 %

Shares of IMNM stock opened at $9.35 on Thursday. Immunome, Inc. has a 52-week low of $8.97 and a 52-week high of $30.96. The stock has a market cap of $583.63 million, a PE ratio of -1.15 and a beta of 1.90. The business has a 50-day simple moving average of $11.32 and a 200-day simple moving average of $12.77.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.